These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31988972)

  • 1. A Phase 3 Study to Compare Delafloxacin With Moxifloxacin for the Treatment of Adults With Community-Acquired Bacterial Pneumonia (DEFINE-CABP).
    Horcajada JP; Salata RA; Álvarez-Sala R; Nitu FM; Lawrence L; Quintas M; Cheng CY; Cammarata S;
    Open Forum Infect Dis; 2020 Jan; 7(1):ofz514. PubMed ID: 31988972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial.
    McCurdy S; Nenninger A; Sheets A; Keedy K; Lawrence L; Quintas M; Cammarata S
    Int J Infect Dis; 2020 Aug; 97():374-379. PubMed ID: 32534142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial.
    McCurdy S; Keedy K; Lawrence L; Nenninger A; Sheets A; Quintas M; Cammarata S
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial.
    Alexander E; Goldberg L; Das AF; Moran GJ; Sandrock C; Gasink LB; Spera P; Sweeney C; Paukner S; Wicha WW; Gelone SP; Schranz J
    JAMA; 2019 Nov; 322(17):1661-1671. PubMed ID: 31560372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delafloxacin for the treatment of adult patients with community-acquired bacterial pneumonia.
    Bassetti M; Melchio M; Giacobbe DR
    Expert Rev Anti Infect Ther; 2022 May; 20(5):649-656. PubMed ID: 34913817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.
    File TM; Goldberg L; Das A; Sweeney C; Saviski J; Gelone SP; Seltzer E; Paukner S; Wicha WW; Talbot GH; Gasink LB
    Clin Infect Dis; 2019 Nov; 69(11):1856-1867. PubMed ID: 30722059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delafloxacin: A Review in Community-Acquired Pneumonia.
    Lee A; Lamb YN; Shirley M
    Drugs; 2022 Jun; 82(8):913-923. PubMed ID: 35708893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study.
    O'Riordan W; McManus A; Teras J; Poromanski I; Cruz-Saldariagga M; Quintas M; Lawrence L; Liang S; Cammarata S;
    Clin Infect Dis; 2018 Aug; 67(5):657-666. PubMed ID: 29518178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
    File TM; Rewerska B; Vucinic-Mihailovic V; Gonong JRV; Das AF; Keedy K; Taylor D; Sheets A; Fernandes P; Oldach D; Jamieson BD
    Clin Infect Dis; 2016 Oct; 63(8):1007-1016. PubMed ID: 27448679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Delafloxacin in Patients with Community-Acquired Bacterial Pneumonia in the Outpatient Setting: A Budget Impact Model.
    Lodise TP; Tillotson GS; Spargo A; Bozkaya D; Massey J
    Clin Drug Investig; 2020 Oct; 40(10):961-971. PubMed ID: 32651832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin.
    Paukner S; Goldberg L; Alexander E; Das AF; Heinrich S; Patel P; Moran GJ; Sandrock C; File TM; Vidal JE; Waites KB; Gelone SP; Schranz J
    J Glob Antimicrob Resist; 2022 Jun; 29():434-443. PubMed ID: 34788694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities.
    File TM; Alexander E; Goldberg L; Das AF; Sandrock C; Paukner S; Moran GJ
    BMC Pulm Med; 2021 May; 21(1):154. PubMed ID: 33964925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A profile of delafloxacin in the treatment of adults with community-acquired bacterial pneumonia.
    Gómez-Zorrilla S; Sendra E; Horcajada JP
    Expert Rev Clin Pharmacol; 2022 Jun; 15(6):671-688. PubMed ID: 35838033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Community-Acquired Pneumonia: A Focus on Lefamulin.
    Eraikhuemen N; Julien D; Kelly A; Lindsay T; Lazaridis D
    Infect Dis Ther; 2021 Mar; 10(1):149-163. PubMed ID: 33528794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study.
    Pullman J; Gardovskis J; Farley B; Sun E; Quintas M; Lawrence L; Ling R; Cammarata S;
    J Antimicrob Chemother; 2017 Dec; 72(12):3471-3480. PubMed ID: 29029278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections.
    Giordano PA; Pogue JM; Cammarata S
    Clin Infect Dis; 2019 Apr; 68(Suppl 3):S223-S232. PubMed ID: 30957167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.
    Zhanel GG; Hartel E; Adam H; Zelenitsky S; Zhanel MA; Golden A; Schweizer F; Gorityala B; Lagacé-Wiens PR; Walkty AJ; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2016 Dec; 76(18):1737-1757. PubMed ID: 27909995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omadacycline in the treatment of community-acquired bacterial pneumonia in patients with comorbidities: a
    Rodriguez GD; Warren N; Yashayev R; Chitra S; Amodio-Groton M; Wright K
    Front Med (Lausanne); 2023; 10():1225710. PubMed ID: 37575994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delafloxacin for the treatment of respiratory and skin infections.
    Bassetti M; Della Siega P; Pecori D; Scarparo C; Righi E
    Expert Opin Investig Drugs; 2015 Mar; 24(3):433-42. PubMed ID: 25604710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL).
    Barrera CM; Mykietiuk A; Metev H; Nitu MF; Karimjee N; Doreski PA; Mitha I; Tanaseanu CM; Molina JM; Antonovsky Y; Van Rensburg DJ; Rowe BH; Flores-Figueroa J; Rewerska B; Clark K; Keedy K; Sheets A; Scott D; Horwith G; Das AF; Jamieson B; Fernandes P; Oldach D;
    Lancet Infect Dis; 2016 Apr; 16(4):421-30. PubMed ID: 26852726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.